A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Active Psoriatic Arthritis
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Izokibep (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Sponsors ACELYRIN
- 28 Jun 2024 Planned End Date changed from 7 Nov 2024 to 14 Nov 2024.
- 15 Jun 2024 Results assessing the efficacy and safety of IZO through wk 16 presented at the 25th Annual Congress of the European League Against Rheumatism
- 05 Jun 2024 According to an ACELYRIN media release, data from the study will be shared as a late breaking oral presentation at the 2024 European Alliance of Associations for Rheumatology Congress taking place June 12-15 in Vienna, Austria.